Search Results
Your search for Matthew matches 8054 pages
Showing 7651 - 7700Investigators Attempt to Increase Lapatinib Exposure Through Intermittent Dosing in HER2-Positive Breast Cancer
HER3 links with HER2 in a reciprocal relationship including negative feedback signaling that can upregulate HER2-HER3 signaling to compensate for HER2 inhibition. This signal-buffering capacity protects HER2-HER3 against a nearly 2-log inhibition of HER2 catalytic activity. The anti-HER2 tyrosine...
Breast Cancer Risk Variant Associated With Increased Lung Cancer Risk in Women
In a study reported in the Journal of the National Cancer Institute, Park et al examined single nucleotide polymorphisms (SNPs) associated with other cancers for potential associations with lung cancer. They found that the breast cancer SNP LSP1 rs3817198 was associated with significant risk of...
Quality-of-Life Study in NCIC MAP.3 Trial Shows Limited Negative Impact of Daily Exemestane in Breast Cancer Prevention
The National Cancer Institute of Canada (NCIC) Clinical Trials Group MAP.3 (Mammary Prevention 3) trial showed that daily exemestane treatment reduced invasive breast cancer risk by 65% among postmenopausal women. In a quality-of-life study in the MAP.3 population reported in the Journal of...
ASCO Releases Adapted Guideline on Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer
A majority of cancer patients experience some level of fatigue during their course of treatment, and approximately 30% contend with persistent fatigue for years after treatment. Fatigue is among the most common and distressing long-term effects of cancer treatment and significantly affects patient...
ASCO Issues Adapted Guideline on Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer
ASCO has adapted the Pan-Canadian Practice Guideline on Screening, Assessment, and Care of Psychosocial Distress (Depression, Anxiety) in Adults With Cancer for use in the screening, assessment, and care of anxiety and depressive symptoms in adults with cancer. The adapted guideline, reported in...
ASCO Releases Guideline on Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers
The American Society of Clinical Oncology has released a clinical practice guideline on prevention and treatment of chemotherapy-induced peripheral neuropathy in adult cancer patients, published in the Journal of Clinical Oncology. The overall incidence of chemotherapy-induced peripheral neuropathy ...
IGH@ Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia
In a study reported in the Journal of Clinical Oncology, Russell et al found that immunoglobulin heavy chain (IGH@) translocations were present in a substantial proportion of younger patients with acute lymphoblastic leukemia (ALL), including those with B-cell precursor ALL. However, IGH@...
Worse Progression-Free Survival With Addition of Cetuximab to Chemotherapy in Patients With Resectable Colorectal Liver Metastasis
Surgery for liver metastasis from colorectal cancer is associated with overall survival of approximately 40% at 5 years, and progression-free survival is increased with the addition of oxaliplatin and fluorouracil (5-FU). The addition of cetuximab (Erbitux) to chemotherapy has produced a survival...
ASCO Endorses SSO/ASTRO Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer
As reported in the Journal of Clinical Oncology by Buchholz et al, ASCO has endorsed the recently published Society of Surgical Oncology (SSO) and American Society for Radiation Oncology (ASTRO) consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stage I...
Phase II Study Suggests Promise of Intermittent Chemotherapy Plus Continuous Cetuximab in Advanced KRAS Wild-Type Colorectal Cancer
In a phase II study (COIN-B) reported in The Lancet Oncology, Wasan et al examined the addition of continuous or intermittent cetuximab (Erbitux) to intermittent chemotherapy in previously untreated advanced KRAS wild-type colorectal cancer. Continuous cetuximab appeared to be associated with...
Consumptive Hypothyroidism in GIST Associated With Increased D3 Expression
In a report in The New England Journal of Medicine, Maynard et al discuss identification of consumptive hypothyroidism due to overexpression of thyroid hormone–inactivating enzyme type 3 iodothyronine deiodinase (D3) in a patient with gastrointestinal stromal tumor (GIST) and subsequent...
Crossover Trial Indicates Preference for Pazopanib Over Sunitinib in Patients With Metastatic Renal Cell Carcinoma
A crossover trial reported in the Journal of Clinical Oncology by Escudier et al found that patients with metastatic renal cell carcinoma preferred pazopanib (Votrient) vs sunitinib (Sutent) treatment. Study Details In the double-blind study, 168 patients with no prior systemic therapy for...
Similar Progression-Free Survival With Panitumumab vs Bevacizumab Plus Modified FOLFOX6 in Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
In a phase II trial (PEAK) reported in the Journal of Clinical Oncology, Schwartzberg et al compared the EGFR inhibitor panitumumab (Vectibix) vs the VEGF-A inhibitor bevacizumab (Avastin) combined with modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) in patients with previously...
High t(14;18) Translocation Frequency Predicts Follicular Lymphoma up to 15 Years Later
The t(14;18) translocation is a hallmark and critical event in the development of follicular lymphoma, but it is also detectable in otherwise healthy persons, and its relationship to progression to disease is unclear. In a study reported in the Journal of Clinical Oncology, Roulland et al found...
Validation of Mantle Cell Lymphoma International Prognostic Index in European Mantle Cell Lymphoma Network Trials
The Mantle Cell Lymphoma International Prognostic Index (MIPI) was developed in 2008 as the first prognostic stratification system specific for mantle cell lymphoma (MCL). In a study reported in the Journal of Clinical Oncology, Hoster et al confirmed the validity of MIPI in a cohort of two...
HLA Class I Antigen Expression Predicts Overall Survival Benefit With Aspirin Use in Colon Cancer
In a cohort study reported in JAMA Internal Medicine, Reimers et al found that aspirin use was associated with a significant 47% reduction in mortality risk after diagnosis of colon cancer expressing HLA class I antigen. There was no difference in aspirin benefit according to strong or weak...
Findings of AURELIA Trial Support Consideration of Bevacizumab/Chemotherapy in Carefully Selected Patients With Platinum-Resistant Ovarian Cancer
The recently reported open-label phase III AURELIA trial showed that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvements in progression-free survival, the primary study endpoint, and objective response rate in women with recurrent platinum-resistant ovarian...
Addition of Bevacizumab to Chemotherapy Improves Patient-Reported Outcomes in Platinum-Resistant Ovarian Cancer
The recently reported open-label phase III AURELIA trial showed that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvement in progression-free survival, the primary study endpoint, and objective response rate in women with recurrent platinum-resistant ovarian...
Adding Bevacizumab to Chemotherapy Improves Progression-Free Survival in Platinum-Resistant Recurrent Ovarian Cancer
Single-agent chemotherapy is standard in platinum-resistant ovarian cancer. In the open-label phase III AURELIA trial reported in the Journal of Clinical Oncology, Pujade-Lauraine et al found that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvement in...
18F-FDOPA PET Predicts Good Prognosis as Soon as 2 Weeks After Start of Antiangiogenic Therapy in Recurrent High-Grade Glioma
In a study reported in Clinical Cancer Research, Schwarzenberg et al found 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-FDOPA) positron-emission tomography (PET) metabolic tumor volume values at 2 weeks after the start of bevacizumab (Avastin) were highly predictive of outcome in patients with ...
MET Immunohistochemistry Expression Is Best Predictor of Benefit From Addition of Onartuzumab to Erlotinib in Advanced NSCLC
A recent phase II study showed progression-free survival and overall survival benefits with the addition of onartuzumab (an antibody directed against MET, a receptor kinase that binds hepatocyte growth factor [HGF]) to erlotinib (Tarceva) in the subset of patients with advanced non–small cell ...
Patient Characteristics and Outcome Differ in Clinical Trial vs General Population Elderly Patients With Hormone Receptor–Positive Breast Cancer
In a study reported in the Journal of the National Cancer Institute, van de Water et al found that Dutch women with hormone receptor–positive breast cancer aged ≥ 65 years at diagnosis who were treated in a clinical trial had significantly fewer comorbid diseases, higher socioeconomic...
Radiofrequency Ablation Reduces Risk of High-Grade Dysplasia and Adenocarcinoma vs Endoscopic Surveillance in Patients With Barrett’s Esophagus
Barrett’s esophagus with low-grade dysplasia increases risk of esophageal adenocarcinoma. In a European study reported in JAMA, Phoa et al assessed whether endoscopic radiofrequency ablation reduced the rate of neoplastic progression compared with endoscopic surveillance in patients with...
Women Are Infrequently First or Corresponding Authors in Collaborative Group Publications in Oncology
As reported in a research letter in JAMA Internal Medicine, Sun et al studied the frequency with which women lead clinical trial publications from organized collaborative groups in oncology. They found that women are very infrequently lead or corresponding authors, with the percentages not changing ...
Phase II Trial Shows Feasibility of Customized Adjuvant Treatment in NSCLC, but Phase III Trial Canceled Due to Unreliability of ERCC1 Readouts
In the phase II Tailored Postsurgical Therapy in Early-Stage NSCLC (TASTE) trial (IFCT-0801), reported in the Journal of Clinical Oncology, Wislez et al examined the feasibility of customized adjuvant treatment based on EGFR mutation status and expression of ERCC1 (excision repair...
Anastrozole Reduces Breast Cancer Incidence in High-Risk Postmenopausal Women
In the phase III IBIS-II trial, reported in The Lancet, Cuzick et al found that aromatase inhibitor therapy with anastrozole reduced risk of breast cancer in postmenopausal women at high risk of the disease. Study Details In this double-blind trial, 3,864 postmenopausal women aged 40 to 70 years...
Ceritinib Highly Active in Patients With ALK-Rearranged Advanced NSCLC, Including Those With Prior Crizotinib Treatment
Non–small cell lung cancer (NSCLC) harboring ALK rearrangement is sensitive to the ALK inhibitor crizotinib (Xalkori), but resistance ultimately occurs. In a phase I study reported in The New England Journal of Medicine, Shaw et al found that the more-potent ALK inhibitor ceritinib was...
Metastatic Neuroblastoma Confined to Distant Lymph Nodes Associated With Better Survival Compared With Other Stage IV Disease
The pattern of metastatic spread is not incorporated into current risk-stratification systems for neuroblastoma. In a retrospective study reported in the Journal of Clinical Oncology, Morgenstern et al found that patients with neuroblastoma with metastatic disease limited to distant lymph nodes...
Prolonged Administration of Azacitidine Improves Response in Myelodysplasia, Less So in Combination With Entinostat
In the phase II US Leukemia Intergroup Trial E1905 reported in the Journal of Clinical Oncology, Prebet et al found that prolonged administration of lower-dose azacitidine produced a high response rate in patients with myelodysplastic syndrome or acute myeloid leukemia (AML) with myelodysplastic...
Tumor Size, Location, and Mitotic Rate, but Not Genotype, Associated With Recurrence-Free Survival in Trial of Adjuvant Imatinib vs Placebo in GIST
The ACOSOG Z9001 (Alliance) study showed that 1 year of adjuvant imatinib (Gleevec) prolonged recurrence-free survival after resection of primary gastrointestinal stromal tumors (GIST). As reported by Corless et al in the Journal of Clinical Oncology, a study evaluating correlation of pathologic...
Continued Event-Free Survival Benefit of Neoadjuvant/Adjuvant Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
As reported by Gianni et al in The Lancet Oncology, long-term follow-up of women with HER2-positive locally advanced breast cancer receiving neoadjuvant chemotherapy alone vs with neoadjuvant and adjuvant trastuzumab (Herceptin) in the phase III NOAH trial has shown continued event-free survival...
Omitting Radiotherapy in Early PET-Negative Stage I/II Hodgkin Lymphoma Is Associated With Increased Risk of Early Relapse
The EORTC/LYSA/FIL Intergroup H10 trial assessed whether omitting involved-node radiotherapy would affect progression-free survival in patients with negative early positron-emission tomography (PET) scans after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) compared with...
Locoregional Progression of Cervical Cancer Follows Reverse Ontogenetic Sequence
In a study reported in The Lancet Oncology, Höckel et al demonstrated that locoregional progression of cervical cancer follows the reverse sequence of establishment of adult tissues in ontogeny. Ontogenetic staging was a better predictor of survival than pathologic staging. Previous work by...
Phase II Study Suggests Benefit of Adding Rituximab to Chlorambucil in First-Line Treatment for Chronic Lymphocytic Leukemia
In a UK phase II study reported in the Journal of Clinical Oncology, Hillmen et al assessed the safety and activity of adding rituximab (Rituxan) to chlorambucil (Leukeran) in first-line treatment of chronic lymphocytic leukemia (CLL). Such a regimen may be an alternative to fludarabine-based...
Stool Multitarget DNA Test More Sensitive, But Less Specific Than Fecal Immunochemical Test for Colorectal Cancer Screening in Persons at Average Risk
In a study reported in The New England Journal of Medicine, Imperiale et al found that a noninvasive, multitarget stool DNA test—including assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, β-actin, and hemoglobin—was significantly more sensitive but significantly less ...
Risk Factors for Gastrointestinal Adverse Events Studied in Setting of First-Line Bevacizumab/Chemotherapy for Ovarian Cancer
As reported in the Journal of Clinical Oncology, Burger et al assessed risk factors for gastrointestinal adverse events in women with advanced ovarian cancer receiving first-line bevacizumab (Avastin)/chemotherapy with or without bevacizumab maintenance or chemotherapy alone in the phase III...
Socioeconomic Disparities in Mortality After Cancer Surgery Reflect Higher Failure-to-Rescue Rates in Hospitals Treating More Low-Income Patients
Although it has been found that lower socioeconomic status is associated with higher operative mortality, the factors explaining this disparity have not been clearly defined. In a study of major cancer surgery reported in JAMA Surgery, Reames et al found that hospitals with the highest proportion...
Preclinical Study Suggests Benefits of Increased Tumor Perfusion and Reduced Tumor Hypoxia With Exercise in Prostate Cancer
In a study reported in the Journal of the National Cancer Institute, McCullough et al used an orthotopic rat model of prostate cancer to assess the effects of exercise on tumor hemodynamics and tissue hypoxia. Their findings of enhanced tumor perfusion and diminished tumor hypoxia suggest that...
Analysis of SWOG Trials Indicates No Survival Difference After 1 Year in Cancer Patients Treated In vs Out of Clinical Trials
In a study reported in the Journal of the National Cancer Institute, Unger et al evaluated whether cancer patients from SWOG clinical trials were similar to nontrial patients in baseline characteristics and survival. They found that, overall, trial participation in standard treatment arms did not...
Swedish Study Shows Lower Prostate Cancer Mortality in High-Incidence Areas
In a study reported in the Journal of the National Cancer Institute, Stattin et al found that rates of prostate cancer mortality, excess mortality in men with prostate cancer, and metastatic prostate cancer were lower in counties in Sweden with higher vs lower incidence of prostate cancer that...
Cutaneous Melanoma and Papillary Thyroid Carcinoma: Mutual Increased Risk
In a study reported in JAMA Otolaryngology-Head & Neck Surgery, Oakley et al found that papillary thyroid cancer increases the risk of cutaneous malignant melanoma and vice versa. In addition, the investigators found that patients with both cancers have a high frequency of BRAF V600E mutation. ...
High Circulating Tumor Cell Count at Baseline and Increases in Count During Treatment Linked to Reduced Survival in Metastatic Breast Cancer
In a pooled analysis of individual patient data reported in The Lancet Oncology, Bidard et al found that baseline circulating tumor cell counts and increases in counts during treatment were highly prognostic in patients with metastatic breast cancer beginning new treatment and that addition of...
Shortening of Leukocyte Telomeres Associated With Increased All-Cause and Breast Cancer–Specific Mortality in Breast Cancer Patients
Short telomeres are associated with increased risk of cancer, but data on telomere length and mortality in breast cancer survivors are inconsistent. In a study reported in the Journal of the National Cancer Institute, Duggan et al found that decreases in telomere length between baseline and 30...
No Difference in Bone Mineral Density Changes With Adjuvant Exemestane vs Anastrozole in Women With Early Breast Cancer
In a companion study (MA.27B) to the open-label phase III National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) MA.27 trial in women with early breast cancer reported in The Lancet Oncology, Goss et al found that adjuvant aromatase inhibitor treatment with exemestane, a mildly...
Circulating Tumor Cell Count and Early Change in Count Are Prognostic for Survival in First-Line Docetaxel Treatment of Prostate Cancer
As reported in the Journal of Clinical Oncology, Goldkorn et al assessed the prognostic value of circulating tumor cell counts in patients with metastatic castration-resistant prostate cancer receiving standard first-line docetaxel plus prednisone with or without atrasentan in the SWOG S0421 trial. ...
No Overall Survival Benefit of First-Line Doxorubicin Plus Ifosfamide vs Doxorubicin Alone in Advanced Soft-Tissue Sarcoma
In the open-label, phase III EORTC 62012 trial reported in The Lancet Oncology, Judson et al found that doxorubicin plus ifosfamide was not associated with any overall survival advantage compared with doxorubicin alone in patients with advanced or metastatic soft-tissue sarcoma. Progression-free...
Children With Cancer, Parents, and Providers Value Patient-Reported Outcomes Feedback
In a pilot trial (PediQUEST) reported in the Journal of Clinical Oncology, Wolfe et al assessed the effects of use of the PediQUEST electronic patient-reported feedback survey on health-related quality of life in children with advanced cancer. Although few significant improvements were observed,...
Stereotactic Body Radiation Costs Less but Is Associated With More Genitourinary Toxicity vs Intensity-Modulated Radiation Therapy for Prostate Cancer
In a retrospective Medicare-based study reported in the Journal of Clinical Oncology, Yu et al found that although stereotactic body radiation therapy is associated with lower treatment costs than intensity-modulated radiation therapy in treatment of prostate cancer, it is also associated with...
Only Small Number of Genetic Markers Show Association With Capecitabine Toxicity in Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, Rosmarin et al assessed the association of reported fluorouracil (5-FU) toxicity genetic markers with occurrence of capecitabine toxicity of grade ≥ 3 in the QUASAR2 trial in colorectal cancer and with occurrence of capecitabine and 5-FU...
Satisfaction With Work-Life Balance Among U.S. Oncologists Lower Than Other Medical Specialties, Survey Says
The American Society of Clinical Oncology (ASCO) conducted a survey of U.S. oncologists between October 2012 and March 2013, evaluating satisfaction with work-life balance and career plans. The findings, reported in the Journal of Clinical Oncology by Shanafelt et al, indicate that most are...
